|First Author, Year (Ref. #)||N||Design||Protocol||Type of Cardiac Surgery||Primary Endpoint||Definition of AF to Meet Endpoint||Follow-Up|
|Imazio et al., 2011 (13)||336||Prospective, randomized, double blind, placebo controlled||Colchicine/placebo = 1 mg BID for 1 day (started on third day post-op), maintenance dose 0.5 mg BID for 1 month (≥70 kg and half dose if ≤70 kg)||Cardiac surgery (CABG, valvular surgery, aorta surgery, combined surgery, and others)||Rate of postoperative AF on placebo/colchicine treatment∗||No consistent P waves before each QRS complex and irregular ventricular rate, lasting more than 5 min.||12 months|
|Imazio et al., 2014 (15)||360||Prospective, randomized, double blind, placebo controlled||Colchicine/placebo = 0.5 mg BID (or 0.5 mg daily if ≤70 kg) starting between 48 and 72 h before surgery and continued for 1 month||Cardiac surgery (included CABG, valvular disease, aortic disease and combined surgery)||Postpericardiotomy syndrome within 3 months; secondary endpoint was postoperative AF in 3 months after cardiac surgery||AF lasting more than 30 s.||3 months|
|Sarzaeem et al., 2014 (14)||216||Prospective, randomized, double blind, placebo controlled||Colchicine/placebo = 1 mg night before and on day of surgery, 0.5 mg BID for 5 days post-op||CABG only||Incidence of postoperative AF||AF for at least 10 min||6 months|
AF = atrial fibrillation; BID = twice daily; CABG = coronary artery bypass grafting.
↵∗ Post-operative AF events in day 1 and 2 were excluded from the analysis as therapy was initiated on day 3.